1Koyama T,Mikami Y,Saga T,et al.Secondary ovarian tumors:spectrum of CT and MR features with pathologic correlation[J].Abdom Imaging,2007,32(6):784-795.
2Manini C,Pietribiasi F,Sapino A,et al.Cistoadenocarcinoma sieroso dell'ovaio con simultanea metastasi mammaria.Descrizione di un caso[J].Pathologica,1998,90 (2):152-155.
3Chen S,Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J].J Clin Oncol,2007,25 (11):1329-1333.
4Antoniou A,Pharoah PD,Narod S,et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history:a combined analysis of 22 studies[J].Am J Hum Genet,2003,72 (5):1117-1130.
5Atchley DP,Albarracin CT,Lopez A,et al.Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer[J].J Clin Oncol,2008,26(26):4282-4288.
6Bruchim I,Fishman A,Friedman E,et al.Analyses of p53 expression pattern and BRCA mutations in patients with double primary breast and ovarian cancer[J].Int J Gynecol Cancer,2004,14 (2):251-258.
7Wolff EF,Martel M,Gwin K,et al.Synchronous primary breast and ovarian cancer with ovarian cancer metastases to a breast sentinel lymph node[J].Breast J,2009,15 (2):203-205.
8Sandor V,Reed E,Sarosy G,et al.Synchronous inflammatory breast cancer and advanced ovarian carcinoma:a case with prolonged disease-free survival[J].Ann Oncol,1999,10 (5):585-588.
9Aksoy S,Dizdar O,Altundag K,et al.Weekly paclitaxel in the adjuvant treatment of breast cancer[J].N Engl J Med,2008,358 (3):310.
10Byrski T,Gronwald J,Huzarski T,et al.Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J].J Clin Oncol,2010,28(3):375-379.
